Skip to main content
SpringerLink
Log in

Predictive Markers of Breast Cancer: ER, PR, and HER2

  • Chapter
  • First Online:
Handbook of Practical Immunohistochemistry

  • 2602 Accesses

Abstract

With the new role of immunohistochemistry as a test to guide the use of specific therapies, new demands for quantitative accuracy and reproducibility have been placed on laboratories. In response to this need increased quality of IHC testing, the College of American Pathologists (CAP) has released guidelines for the validation, performance, and ongoing quality management of receptor testing in breast cancer cases. This chapter reviews the new requirements of these testing guidelines to help laboratories adopt these best practices. Information is offered on the FDA approval of ­current antibodies for this testing. Diagrams illustrate the recommended testing algorithm combining results of immunohistochemical and in situ hybridization testing for HER2. Photomicrographs of ­positive, negative, and equivocal staining reactions are provided to aid in the interpretation of immunohistochemical and in situ hybridization assays. Figures demonstrating the use of appropriate and inappropriate internal control reactions serve to help decide, if results are valid and can be reported or should be rejected.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18–43.

    PubMed  CAS  Google Scholar 

  2. Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006;4 Suppl 3:S1–22.

    Google Scholar 

  3. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(6):907–22.

    PubMed  Google Scholar 

  4. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing–National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94(11):852–4.

    Article  PubMed  Google Scholar 

  5. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002;94(11):855–7.

    Article  PubMed  Google Scholar 

  6. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24(19):3032–8.

    Article  PubMed  Google Scholar 

  7. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008;26:2473–81.

    Article  PubMed  Google Scholar 

  8. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P, Rasmussen BB, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol. 2007;25:3846–52.

    Article  PubMed  Google Scholar 

  9. Bloom K, Harrington D. Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol. 2004;121(5):620–30.

    Article  PubMed  Google Scholar 

  10. Munro AF, Cameron DA, Bartlett JM. Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge. Oncogene. 2010;29(38):5231–40.

    Article  PubMed  CAS  Google Scholar 

  11. Olayioye MA. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001;3(6):385–9. doi:10.1186/bcr327. PMID 11737890.

    Article  PubMed  CAS  Google Scholar 

  12. Libermann TA et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230(4730):1132–9.

    Article  PubMed  Google Scholar 

  13. Idirisinghe PK, Thike AA, Cheok PY, Tse GM, Lui PC, Fook-Chong S, et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol. 2010;133(3):416–29.

    Article  PubMed  Google Scholar 

  14. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320–68.

    Article  PubMed  CAS  Google Scholar 

  15. Mohsin SK. HER2 testing: state of the laboratories. Arch Pathol Lab Med. 2010;134(5):660–6. Online publication date: 1 May 2010.

    PubMed  Google Scholar 

  16. Downey L, Livingston RB, Koehler M, Arbushites M, Williams L, Santiago A, et al. Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin Cancer Res. 2010;16(4):1281–8.

    Article  PubMed  CAS  Google Scholar 

  17. Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Rüschoff J, et al. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol. 2009;132(4):539–48.

    Article  PubMed  CAS  Google Scholar 

  18. Francis GD, Jones MA, Beadle GF, Stein SR. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol. 2009;18(2):88–95.

    Article  PubMed  CAS  Google Scholar 

  19. Papouchado BG, Myles J, Lloyd RV, Stoler M, Oliveira AM, Downs-Kelly E, et al. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol. 2010;34(6):767–76.

    Article  PubMed  Google Scholar 

  20. Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol. 2002;15(6):657–65.

    Article  PubMed  Google Scholar 

  21. Krishnamurti U, Hammers JL, Atem FD, Storto PD, Silverman JF. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Pathol. 2009;22(8):1044–8.

    Article  PubMed  CAS  Google Scholar 

  22. Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens MR, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol. 2008;26(30):4869–74.

    Article  PubMed  Google Scholar 

  23. Gruver AM, Peerwani Z, Tubbs RR. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol. 2010;63(3):210–9.

    Article  PubMed  Google Scholar 

  24. Mayr D, Heim S, Weyrauch K, Zeindl-Eberhart E, Kunz A, Engel J, et al. Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology. 2009;55(6):716–23.

    Article  PubMed  Google Scholar 

  25. Kato N, Itoh H, Serizawa A, Hatanaka Y, Umemura S, Osamura RY. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH). Pathol Int. 2010;60(7):510–5.

    Article  PubMed  Google Scholar 

  26. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev. 2006;58(4):773–81.

    Article  Google Scholar 

  27. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol. 2005;19(8):1951–9.

    Article  PubMed  CAS  Google Scholar 

  28. Gadkar-Sable S, Shah C, Rosario G, Sachdeva G, Puri C. Progesterone receptors: various forms and functions in reproductive tissues. Front Biosci. 2005;10:2118–30.

    Article  PubMed  CAS  Google Scholar 

  29. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990;9(5):1603–14.

    PubMed  CAS  Google Scholar 

  30. Fisher ER, Anderson S, Dean S, Dabbs D, Fisher B, Siderits R, et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer. 2005;103(1):164–73.

    Article  PubMed  CAS  Google Scholar 

  31. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–81.

    PubMed  CAS  Google Scholar 

  32. Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, le Roanh D, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17:1545–54.

    Article  PubMed  CAS  Google Scholar 

  33. Visvanathan K, Lippman SM, Hurley P, Temin S. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009;27(19):3235–58.

    Article  PubMed  CAS  Google Scholar 

  34. Yamashita H, Yando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer. 2006;13:74–83.

    Article  PubMed  Google Scholar 

  35. Fitzgibbons PL, Murphy DA, Hammond MEH, et al. Recommendations for validating estrogen and progesterone receptor immunohistoche­mistry assays. Arch Pathol Lab Med. 2010;134(6):930–5.

    PubMed  CAS  Google Scholar 

  36. Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003;120:86–92.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Geisinger Medical Center, Danville, PA, 17822, USA

    Jeffrey Prichard

Authors
  1. Jeffrey Prichard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Hicks
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth Hammond
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey Prichard .

Editor information

Editors and Affiliations

  1. , Pathology and Laboratory Medicine, Geisinger Health System, 100 N. Academy Avenue, Danville, 17822, Pennsylvania, USA

    Fan Lin

  2. , Pathology and Laboratory Medicine, Geisinger Medical Center, 100 N. Academy Avenue, Danville, 17822, Pennsylvania, USA

    Jeffrey Prichard

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Prichard, J., Hicks, D., Hammond, E. (2011). Predictive Markers of Breast Cancer: ER, PR, and HER2. In: Lin, F., Prichard, J. (eds) Handbook of Practical Immunohistochemistry. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-8062-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-8062-5_9

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-8061-8

  • Online ISBN: 978-1-4419-8062-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation